Effect of Jiedu Huayu decoction (解毒化瘀汤) on oral mucosal Axin and β-catenin expression in oral submucosal fibrosis model rats

doi:10.19852/j.cnki.jtcm.20240617.001

Abstract

Abstract:

OBJECTIVE: To investigate the protective effect of the Chinese herbal formula of Jiedu Huayu decoction (解毒化瘀汤, JHD) on oral mucosa of rats with oral submucosal fibrosis (OSF) and its potential mechanism of action.

METHODS: Sprague-Dawley male OSF model rats were constructed by injection of betaine and topical rubbing and were randomly grouped and administered by gavage for 4 weeks. Mouth opening and buccal mucosa scores interleukin levels and the expression of Axin and β-catenin proteins or genes were measured before and after drug administration.

RESULTS: After treatment with JHD the buccal mucosal lesions of rats were significantly reduced Axin protein and mRNA expression were significantly increased β-catenin protein and mRNA expression were significantly decreased interleukin-1β and interleukin-6 levels were decreased and interleukin-10 levels were increased.

CONCLUSION: The mechanism of action of JHD can effectively alleviate the pathological damage of buccal mucosa in OSF rats which may be related to the promotion of Axin expression and inhibition of β-catenin expression.

Key words: Axin protein, beta catenin, oral submucosal fibrosis, oral mucosa, Jiedu Huayu decoction

ZHU Xuan, LOU An, ZHU Keke, RUAN Mingyu. Effect of Jiedu Huayu decoction (解毒化瘀汤) on oral mucosal Axin and β-catenin expression in oral submucosal fibrosis model rats[J]. Journal of Traditional Chinese Medicine, 2024, 44(4): 688-693.

Figures/Tables 6

Table 1 Maximum mouth opening and buccal mucosa score of rats in each group ($\bar{x}±s$)

Group	n	Maximal mouth opening (mm)				Buccal mucosa score (point)
Group	n	0 week		2 weeks	4 weeks	0 week	2 weeks	4 weeks
CON	10	20.40±0.91	20.73±1.01		21.31±0.87	0.00	0.00	0.00
MOD	10	15.60±0.47^a	15.75±0.55		15.75±0.57	2.00±0.47^a	2.20±0.63	2.20±0.55
POD	10	15.40±0.77	17.93±0.72^b		20.44±0.00^c	2.00±0.87	1.70±0.40^b	1.40±0.63^c
JHD-H	10	15.73±0.53	16.81±0.79^b		19.50±0.00^c	2.00±0.43	1.80±0.20^b	1.50±0.52^c
JHD-L	10	15.55±0.97	15.71±0.63		15.73±0.72	2.00±0.65	1.90±0.40	1.80±0.37

Table 2 Expression of IL-1β, IL-6 and IL-10 in serum of each group ($\bar{x}±s$

Group	n	IL-1β	IL-6	IL-10
CON	10	15.97±2.69	74.50±7.84	126.86±8.74
MOD	10	38.47±2.34^a	138.65±5.02^d	90.58±13.95^d
POD	10	32.32±1.79^b	118.32±5.86^b	144.73±6.83^b
JHD-H	10	26.25±1.78^c	115.47±6.24^c	135.59±7.89^c
JHD-L	10	20.08±1.87^c	98.45±7.09^c	128.48±6.3

Figure 1 Hematoxylin-eosin staining of the buccal mucosa of rats in each group (× 200) A: CON; B: MOD; C: POD; D: JHD-H; E: JHD-L. The JHD-H and JHD-L groups were given 23.6 and 11.8 g/kg of Chinese medicine by gavage (1 and 2 times the daily adult dose as the equivalent dose which was converted to 60 kg for normal adults) and the POD group was given 400 mg/kg of hydrocortisone by gavage for 4 weeks once per day. CON: control group; MOD: model group; POD: positive drug; D. JHD-H: high-dose Jiedu Huayu decoction; JHD-L: low-dose Jiedu Huayu decoction.

Figure 2 Staining of Axin and β-catenin in the mucosa of each group (SP, × 400) A: expression of Axin in immunohistochemical. A1: CON; A2: MOD; A3: POD; A4: JHD-H; A5: JHD-L. B: expression of β-catenin in immunohistochemical. B1: CON; B2: MOD; B3: POD; B4: JHD-H; B5: JHD-L. The JHD-H and JHD-L groups were given 23.6 and 11.8 g/mg of Chinese medicine by gavage (2 and 1 times the daily adult dose as the equivalent dose which was converted to 60 kg for normal adults) and the POD group was given 400 mg/kg of hydrocortisone by gavage for 4 weeks once per day. CON: control group; MOD: model group; POD: positive drug; D. JHD-H: high-dose Jiedu Huayu decoction; JHD-L: low-dose Jiedu Huayu decoction.

Figure 3 Relative mRNA expression levels of Axin and β-catenin in the mucosa of each group A: relative mRNA expression levels of Axin in the mucosa of each group. B: relative mRNA expression levels of β-catenin in the mucosa of each group. CON: control group. MOD: model group, POD: positive drug. JHD-H: high-dose Jiedu Huayu decoction (23.6 g/kg). JHD-L: low-dose Jiedu Huayu decoction (11.8 g/kg). The POD group was given 400 mg/kg of hydrocortisone by gavage for 4 weeks once per day. One-way analysis of variance and Student-Newman-Keuls-q test for Chi-squareness or Kruskal Wallis H test were applied. The data measured in this research were expressed as mean ± standard deviation (n = 3). aP < 0.01 vs the CON group; bP < 0.01, cP < 0.05 vs the MOD group.

Figure 4 Relative protein expression levels of Axin and β-catenin in the mucosa of each group A: expression of Axin and β-catenin was examined by Western blotting; B: relative protein expression levels of Axin in the mucosa of each group; C: relative protein expression levels of β-catenin in the mucosa of each group. CON: control group, MOD: model group, POD: positive drug, JHD-H: high-dose Jiedu Huayu decoction (23.6 g/kg), JHD-L: low-dose Jiedu Huayu decoction (11.8 g/kg). The POD group was given 400 mg/kg of hydrocortisone by gavage for 4 weeks once per day. One-way analysis of variance and Student-Newman-Keuls-q test for Chi-squareness or Kruskal Wallis H test were applied. The data measured in this research were expressed as mean ± standard deviation (n = 3). aP < 0.01 vs the CON group; bP < 0.01, cP < 0.05 vs the MOD group.

References 19.

1.	Cai H, Song LW. Clinical observation on the treatment of oral submucosa fibrosis with Glycyrrhiza glabra combined with Si Miao Yong An Tang plusreduction. Zhong Hua Zhong Yi Yao Xue Kang 2016; 34: 1486-8.
2.	Jian XC, Gao X. Etiology pathogenesis diagnosis and treatment of oral submucosal fibrous lesions. Kou Qiang Ji Bing Fang Zhi 2021; 29: 217-25.
3.	Peng Q, Li HY, Chen J, et al. Oral submucous fibrosis in Asian countries. J Oral Pathol Med 2020; 49: 294-304. DOI PMID
4.	Arakeri G, Patil SG, Aljabab AS, et al. Oral submucous fibrosis: an update on pathophysiology of malignant transformation. J Oral Pathol Med 2017; 46: 413-7. DOI PMID
5.	Shih YH, Wang TH, Shieh TM, et al. Oral submucous fibrosis: a review on etiopathogenesis diagnosis and therapy. Int J Mol Sci 2019; 20: 2940.
6.	Chowdhury P, Nagamalini BR, Singh J, et al. Expressionof β-catenin in oral leukoplakia and oral submucous fibrosis: an immunohistochemical study. J Oral Maxillofac Pathol 2021; 25: 124-30.
7.	Katase N, Lefeuvre M, Tsujigiwa H, et al. Knockdown of Dkk-3 decreasescancer cell migration and invasion independently of the Wnt pathways in oral squamous cell carcinoma-derived cells. Oncol Rep 2013; 29: 1349-55. DOI PMID
8.	Zhang L, Tan J, Liu YP, et al. Effects of curcumin extract on TGF-β_1 IL-1 and Bcl-2 in OSF model rats and related mechanisms. Yi Nan Bing Za Zhi 2021; 20: 1152-6.
9.	Adhikari S, Rimal J, Maharjan IK, et al. Efficacy of curcumin in combination with intralesional dexamethasone with hyaluronidase in the treatment of oral submucous fibrosis: a randomized controlled trial. Asian Pac J Cancer Prev 2022; 23: 3125-32.
10.	Muller S, Tilakaratne WM. Update from the 5th edition of the world health organization classification of head and neck tumors: tumours of the oral cavity and mobile tongue. Head Neck Pathol 2022; 16: 54-62. DOI PMID
11.	Yang B, Fu MF, Tang ZG. Construction of a rat oral submucosal fibrosismodel by betaine and mechanical stimulation. Hua Xi Kou Qiang Yi Xue Za Zhi 2019; 37: 260-4.
12.	Shetty SS, Sharma M, Fonseca FP, et al. Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma. Jpn Dent Sci Rev 2020; 56: 97-108.
13.	He Y, Jianng X. The role of epithelial-mesenchymal transition in oralsquamous cell carcinoma and oral submucous fibrosis. Clin Chim Acta 2007; 383: 51-6.
14.	Ge WS, Wang YJ, Wu JX, et al. β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Mol Med Rep 2014; 9: 2145-51.
15.	Bai Y, Sha J, Kanno T. The role of carcinogenesis-related biomarkers in the wnt pathway and their effects on Epithelial-Mesenchymal Transition (EMT) in oral squamous cell carcinoma. Cancers (Basel) 2020; 12: 555.
16.	Ji L, Lu B, Zamponi R, et al. USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin. Nat Commun 2019; 10: 4184. DOI PMID
17.	Li YC, Tan J, Chen A, et al. Effect of Dan Xuan Kou Kang on TGFβ expression in rats with oral submucosa fibrosis. Xin Zhong Yi 2006; 38: 89-91.
18.	Tan J, Chen A. Clinical observation on the treatment of oral submucosal fibrosis with blood activation and fibrillation formula. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2001; 8: 71-2.
19.	Yu Y. Clinical observation on the treatment of oral lichen planus with detoxifying and stasis-removing herbs combined with tretinoin oral ointment. Zhong Guo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu 2021; 19: 136-7.

[1]	WU Jieya, HOU Li, ZHANG Xiaoyuan, Elizabeth Gullen, GAO Chong, WANG Jing. Efficacy of Yisui granule (益髓颗粒) on myelodysplastic syndromes in SKM-1 mouse xenograft model through suppressing Wnt/β-catenin signaling pathway [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 78-87.
[2]	DONG Lei, XU Pei. Danzhi Jiangtang capsule (丹蛭降糖胶囊) alleviate hyperglycemiaand periodontitis via Wnt/β-catenin signaling in diabetic rats [J]. Journal of Traditional Chinese Medicine, 2021, 41(4): 608-616.
[3]	Zheng Lixiang, Zheng Qing, Yu Zhipeng, Wang Jian, Ren Xiaoying, Gong Yan, Yang Xue, Hunag Ping, Weng Meizhi, Liu Hongning, Liu Haizhou. Liuwei Dihuang pill suppresses metastasis by regulating the wnt pathway and disrupting β-catenin/T cell factor interactions in a murine model of triple-negative breast cancer [J]. Journal of Traditional Chinese Medicine, 2019, 39(06): 826-832.
[4]	Su Tao, Wang Xinning, Li Chunyu, Bai Jingxuan, Chi-Yan Cheng, Fu Xiuqiong, Li Ting, Yu Zhiling. An ethanolic extract of Bailian(Radix Ampelopsis Japonicae):demonstration of colorectal cancer treatment efficacy via inhibition of β-catenin signaling in vitro [J]. Journal of Traditional Chinese Medicine, 2019, 39(03): 339-345.

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us